Canadian Journal of Gastroenterology and Hepatology

Research Article

Higher Neutrophil-to-Lymphocyte Ratio (NLR) Is a Preoperative Inflammation Biomarker of Poor Prognosis in HIV-Infected Patients with Colorectal Cancer: A Retrospective Study

Table 1

Relationship between NLR subgroups and clinicopathological features in CRC patients living with HIV.


Clinicopathological features	Low NLR group (n = 40)	High NLR group (n = 17)	values

Gender			0.413
Male	33 (82.5%)	16 (94.1%)
Female	7 (17.5%)	1 (5.9%)
Age			0.369
Mean (SD)	59.5 (10.9)	55.4 (15.1)
Median [MIN, MAX]	61 [29, 80]	58 [25, 78]
BMI			0.061
Mean (SD)	21.3 (2.5)	19.9 (1.8)
Median [MIN, MAX]	20.9 [15.9, 28.5]	20.2 [16.1, 23.9]
Hypertension			0.146
No	36 (90.0%)	14 (82.4%)
Yes	4 (10.0%)	3 (17.6%)
DM			0.657
No	35 (87.5%)	16 (94.1%)
Yes	5 (12.5%)	1 (5.9%)
TB			0.511
No	39 (97.5%)	16 (94.1%)
Yes	1 (2.5%)	1 (5.9%)
Smoking			0.253
No	31 (77.5%)	16 (94.1%)
Yes	9 (22.5%)	1 (5.9%)
Alcohol abuse			1
No	35 (87.5%)	15 (88.2%)
Yes	5 (12.5%)	2 (11.8%)
Intestinal obstruction			0.109
No	36 (90.0%)	12 (70.6%)
Yes	4 (10.0%)	5 (29.4%)
Hyperlipidemia			0.191
No	30 (75.0%)	16 (94.1%)
Yes	10 (25.0%)	1 (5.9%)
Duration of HIV infection			0.657
Mean (SD)	34.9 (49.8)	34.2 (48)
Median [MIN, MAX]	5.5 [0, 240]	4 [0, 144]
Duration of HIV treatment			0.913
Mean (SD)	33 (48.3)	31.5 (42.7)
Median [MIN, MAX]	4.5 [0, 240]	4 [0, 120]
Tumor location			1
Right	9 (22.5%)	3 (17.6%)
Left	31 (77.5%)	14 (82.4%)
Histology			1
Squamous cell carcinoma	6 (15.0%)	3 (17.6%)
Adenocarcinoma	34 (85.0%)	14 (82.4%)
MMR status			1
dMMR	6 (15.0%)	3 (17.6%)
pMMR	34 (85.0%)	14 (82.4%)
SBR			0.631
1	3 (7.5%)	0 (0.0%)
2	32 (80.0%)	14 (82.4%)
3	5 (12.5%)	3 (17.6%)
R0			0.109
Yes	36 (90.0%)	12 (70.6%)
No	4 (10.0%)	5 (29.4%)
T stage			0.235
I	2 (5.0%)	1 (5.9%)
II	7 (17.5%)	0 (0.0%)
III	18 (45.0%)	8 (47.1%)
IV	13 (32.5%)	8 (47.1%)
N stage			0.078
Nonmetastasis	29 (72.5%)	8 (47.1%)
Metastasis	11 (27.5%)	9 (52.9%)
M stage			0.464
Nonmetastasis	34 (85.0%)	13 (76.5%)
Metastasis	6 (15.0%)	4 (23.5%)
AJCC stage			0.082
I-II	27 (67.5%)	7 (41.2%)
III-IV	13 (33.5%)	10 (58.8%)
CA125 (0–35 U/ml)			0.248
Normal	35 (87.5%)	12 (70.6%)
Increased	5 (12.5%)	5 (29.4%)
CA153 (0–32.3 U/ml)			1
Normal	36 (90.0%)	16 (94.1%)
Increased	4 (10.0%)	1 (5.9%)
CA199 (0–37 U/ml)			0.795
Normal	30 (75.0%)	14 (82.4%)
Increased	10 (25.0%)	3 (17.6%)
AFP (0.89–8.78 ng/ml)			0.879
Normal	38 (95.0%)	17 (100.0%)
Increased	2 (5.0%)	0 (0.0%)
CEA (0–5 ng/ml)			0.124
Normal	29 (72.5%)	8 (47.1%)
Increased	11 (27.5%)	9 (52.9%)
HGB (g/L)			0.675
Mean (SD)	120.3 (19.9)	123.2 (29.2)
Median [MIN, MAX]	117.5 [60, 152]	130 [68, 189]
PLT count (1000 per μl)			0.583
Mean (SD)	192.3 (74.9)	234.6 (139.2)
Median [MIN, MAX]	189 [51, 400]	195 [93, 627]
NEUT count (1000 per μl)			0.001
Mean (SD)	2.6 (0.8)	4.6 (2.5)
Median [MIN, MAX]	2.6 [1.1, 5.2]	4 [1.3, 9.9]
LYMPH count (1000 per μl)			<0.001
Mean (SD)	1.5 (0.5)	1 (0.4)
Median [MIN, MAX]	1.5 [0.6, 3]	1.1 [0.4, 1.8]
MONO count (1000 per μl)			0.291
Mean (SD)	0.4 (0.1)	0.5 (0.2)
Median [MIN, MAX]	0.4 [0.1, 0.7]	0.4 [0.2, 1]
ALB (g/L)			0.222
Mean (SD)	39.1 (4.2)	40.3 (4.3)
Median [MIN, MAX]	39 [32.2, 47.8]	40.6 [30, 46.3]
CD3 count (per μl)			0.001
Mean (SD)	1102.9 (390.9)	759.8 (279.6)
Median [MIN, MAX]	1076 [376, 2363]	715 [344, 1310]
CD8 count (per μl)			0.001
Mean (SD)	758.8 (374.3)	457.6 (184.7)
Median [MIN, MAX]	695 [158, 1918]	458 [142, 931]
CD4 count (per μl)			0.209
Mean (SD)	305.3 (155.7)	259.2 (186)
Median [MIN, MAX]	282 [43, 729]	230 [13, 806]
CD4/CD8			0.154
Mean (SD)	0.5 (0.4)	0.6 (0.4)
Median [MIN, MAX]	0.4 [0, 1.6]	0.6 [0, 1.8]

DM: diabetes mellitus; TB: tuberculosis infection status; MMR: mismatch repair; SBR: Scarff-Bloom-Richardson score; NLR: neutrophil-lymphocyte ratio; AFP: alpha fetoprotein; CEA: carcinoembryonic antigen; HGB: hemoglobin; PLT: platelet; NEUT: neutrophil; LYMPH: lymphocyte; MONO: monocyte; ALB: albumin.